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objections about the risk factor of mortality in chronic
kidney disease patients. Proteinuria that is defined as urinary
protein excretion of greater than 150 mg/day is a widely
available and cost-effective marker of cardiovascular risk.2
There is strong evidence that proteinuria is associated with an
increase in adverse clinical outcomes, including increased
mortality in not only chronic kidney disease patients but also
subjects with a normal glomerular filtration rate.3,4 However,
they did not include proteinuria either in univariate or
multivariate analysis in their study.1 It is also important to
note that due to the intraindividual variability of urinary
albumin excretion, the estimated risk of death associated with
microalbuminuria may be underestimated.3 In a study by
Klausen et al.3 it is clearly reported that microalbuminuria is
a strong determinant of coronary heart disease and death
independently of age, sex, hypertension, diabetes mellitus,
renal function, and lipids. Similarly in another study by
Culleton et al.4 of 2,582 people, proteinuria is shown to be an
independent significant risk factor for all-cause mortality in
both genders.
In the study by Kovesdy et al.,1 patients were divided into
four groups according to their intact parathyroid hormone
levels. It is clearly seen that there is a statistically significant
difference between those groups for proteinuria levels. This
may be the reason or at least one of the contributing factors
for increased mortality in the high parathyroid hormone
group. Increased parathyroid hormone may be a major risk
factor but it is obvious that proteinuria is also statistically
significantly high in high parathyroid hormone groups. In
adjustment analysis, they took age, race, body mass index,
smoking, comorbidities, estimated growth factor receptor,
serum calcium, phosphorus, albumin and cholesterol levels,
and the use of activated vitamin D and calcium-containing
medications but not proteinuria, which is known to be one of
the most important independent risk factors in end stage
renal failure development and mortality. In multivariable
analysis, proteinuria should be taken into consideration.
Finally, in our opinion, proteinuria is an important factor
increasing mortality in those patients and this study should
be reconsidered in this aspect.
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We appreciate the interest shown by Kanbay et al. in
our paper.1 They question our decision to exclude
proteinuria from multivariable analyses that examined
the association between serum intact parathyroid hormone
(PTH) level and mortality in patients with nondialysis-
dependent chronic kidney disease stages 3–5. The decision
to exclude proteinuria was based on the following
considerations: first, proteinuria does not satisfy criteria
for a confounder in the association between PTH and
mortality, because it has no independent effect on serum
PTH concentration, even though it might affect mortality.2
Whereas Kanbay et al. are correct in pointing out a
discrepancy in the magnitude of proteinuria among our
patients at different PTH levels, this finding in itself
does not necessarily make proteinuria a confounder.
The said discrepancy can indeed be due to the role of
another independent variable with similar imbalance,
which is also associated with proteinuria, such as the
differences in kidney function and/or blood pressure
among different PTH increments. Second, the decision
not to include proteinuria as a covariate was also driven by
a desire to achieve a more parsimonious multivariable
model, especially as our study population had a relatively
smaller size and a limited number of events. Under these
circumstances including too many covariates can result not
only in less stable summary estimates, but might also
introduce new sources of bias. Finally, including protei-
nuria as a covariate during our sensitivity analyses did not
substantially alter the association between PTH and
mortality.
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